Medical News
.jpg)
Resistance in Enterobacterales is Higher Among People with H...
Clin Infect Dis
In a large clinical study population in the southeastern US from 2000-2018, the prevalence of antibacterial...
14 Oct 2021
A Retrospective Study of Survival and Risk Factors for Morta...
AIDS Res. Ther.
This study demonstrated the substantial mortality rate over the consecutive 5 years of the follow-up period among...
13 Oct 2021
Alcohol, Smoking, Recreational Drug Use and Association with...
HIV Med
Screening and treatment for alcohol, cigarette and drug use should be integrated into HIV outpatient clinics, while...
12 Oct 2021
Sex Differences in HIV Persistence and Reservoir Size during...
Clin Infect Dis
In contrast to men, where the HIV reservoir steadily declines with aging, the HIV reservoir in women is more...
07 Oct 2021
eCMEs
Key Trials
Daily PrEP Verses on Demand PrEP Regimen Coverage CLAI for MSM
The present study determined the impacts of oral tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) on demand verses daily PrEP ...
BRAAVE Trial: Efficacy of Switching to STR of B/F/TAF vs Continuing on Regimen of 2 NRTIs and a Third Agent in Virologically Suppressed HIV Adults
BRAAVE study is the randomized phase 3 study evaluating efficacy and safety of switching to fixed-dose combination of B/F/TAF vs continuing...
Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in People with HIV
The present study evaluated safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in people with HIV (PLHIV) in a well characterised UK cohort....
AMBER and EMERALD Trial: 96-week Resistance Analysis of Once-daily Single Tablet Regimen of D/C/F/TAF in HIV-1 Adults Patients
The present study is a 96-week resistance analysis of AMBER and EMERALD trials, evaluating efficacy and safety of darunavir/cobicistat/emtricitabine...
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Infographics
Currently there is no content under this category.
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6